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Abstract
Objective: To review current literature for the efficacy and safety of treatment for nonalcoholic
fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM).
Data sources: A PubMed literature search from January 1990 to June 2017 was conducted
using the search terms nonalcoholic fatty liver disease, diabetes mellitus, type 2, therapy,
treatment, treat, therapeutics, nonalcoholic fatty liver, nonalcoholic hepatosteatosis, NASH,
NAFLD, metformin, and statin. Bibliographies of chosen articles were reviewed.
Study selection and data extraction: Relevant articles on metformin, thiazolidinediones (TZD),
glucagon-like peptide-1 receptor agonists (GLP-1 RA), and statins for the treatment of NAFLD
which included patients with T2DM were reviewed. A total of 23 relevant studies were found
and included randomized controlled, observational, and open-label designs, as well as three
meta-analyses.
Data synthesis: Metformin combined with weight loss provides a modest improvement in
steatosis and no improvement in fibrosis in patients with NAFLD and T2DM. TZDs showed
positive results on fibrosis and resolution of NASH but at least half of patients studied were
nonresponders. GLP-1 RAs also showed favorable results on reductions in transaminases
and steatosis and improvements in insulin sensitivity and weight loss but lack efficacy data
for resolution of NASH or improvement in fibrosis scores. Statins showed favorable results
on reductions in transaminases but mixed results for improvement in steatosis and fibrosis
scores.
Conclusion: All reviewed treatment options are safe for management of NAFLD in patients
with T2DM but long-term histological improvements are minimal. TZDs are efficacious for
resolution of NASH and improvements in fibrosis but long-term use is required to maintain
these results.

Keywords: diabetes, glucagon-like peptide 1 receptor agonists, nonalcoholic fatty liver disease,
statin, steatohepatitis, thiazolidinediones, treatment, type 2
Received: 14 September 2017; accepted in revised form: 23 October 2017.

Introduction
Nonalcoholic fatty liver disease (NAFLD) is the
most common cause of elevated liver enzymes in
adults in the United States. The term NAFLD is
used to encompass a wide range of liver damage
from simple steatosis to nonalcoholic steatohepatitis
(NASH), advanced fibrosis, and cirrhosis.1,2
Although the pathogenesis of NAFLD and the role
of insulin resistance on its progression has not been

journals.sagepub.com/home/tae

fully defined, the ‘multiple-hit’ hypothesis was
recently developed to explain the role of multiple
insults on the liver which may induce NAFLD.3
This hypothesis replaces the previously defined
‘two-hit’ hypothesis, where a sedentary lifestyle,
obesity, and insulin resistance lead to hepatic steatosis (first hit), which promotes liver inflammation
and cellular injury (second hit).4,5 The multiplehit hypothesis defines insulin resistance as a key
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contributor to the development of NAFLD because
of its impact on increases in de novo lipogenesis and
dysfunction in the release of free fatty acids (FFAs)
and triglycerides from the liver.3,5 These risk factors
are also associated with the development of type 2
diabetes (T2DM), explaining the high rate of these
diseases occurring concomitantly. Studies estimate
the prevalence of hepatic steatosis in patients with
T2DM to be 30–50%.6 The prognosis for patients
with concomitant NAFLD and T2DM is worsened
due to increased risk for life-threatening sequela
such as cardiovascular disease and hepatocellular
carcinoma, highlighting the need for improved
treatment options.
The American Association for the Study of Liver
Diseases, the American College of Gastroenterology,
and the American Gastroenterological Association
published joint practice guidelines in 2012 which
recommend lifestyle interventions (hypocaloric diet
and increased physical activity) and a body weight
reduction of 3–5% to achieve improvement of steatosis; however, up to 10% weight loss is needed to
demonstrate improvements in necroinflammation.7
While there are no drugs approved for the treatment of NASH by the US Food and Drug
Administration (FDA), guidelines recommend
vitamin E as a first-line treatment in individuals
without diabetes. The guidelines also recommend
pioglitazone, but warn most clinical studies were
conducted in patients without diabetes. At the time
of guideline publication, there was not enough evidence to support a recommendation for the use of
metformin or statins as a treatment for NASH, but
the use of statins for dyslipidemia in patients with
NASH is encouraged as they appear safe.
Clinicians often question the safety of common
drug treatments for patients with T2DM and
NASH. In recent years, numerous trials have
been conducted utilizing insulin sensitizers and
statins to treat NASH, which included patients
with T2DM in the study design. The objective of
this literature review is to evaluate the safety and
efficacy of medications for the treatment of
NASH in patients with T2DM.
Methods
A review of published studies using PubMed was
conducted to identify reports pertaining to the
safety and efficacy of pharmacologic treatments of
NAFLD commonly used in patients with T2DM.
One author conducted the search and assessed eligibility, and all authors contributed to the review
16

of data, drafting, and editing of the manuscript.
MeSH terms used in various combinations
included non-alcoholic fatty liver disease, diabetes
mellitus, type 2, therapy, treatment, treat, therapeutics, nonalcoholic fatty liver, nonalcoholic
hepatosteatosis, NASH, NAFLD, metformin,
and statin. PubMed search filters were applied for
published dates between 1 January 1990 and 30
June 2017, English language, adults (age ⩾19
years), clinical trial, meta-analysis, or observational studies. Other articles of interest were
obtained from bibliographies of included articles.
Results
A total of 397 abstracts were initially reviewed for
possible inclusion. Only 23 articles met inclusion
criteria based on relevancy to the study population and outcomes relevant to safety and efficacy
of treatment.
Metformin
Metformin has several mechanisms by which it
helps to reduce blood glucose and improve insulin sensitivity, including decreasing gluconeogenesis in the liver, increasing glucose uptake in the
periphery, and increasing fatty acid oxidation, all
leading to a decrease in cellular insulin production.8,9 Metformin promotes weight loss, is inexpensive, and has long-term data showing safety
and tolerability, making it a viable option in the
treatment of NAFLD.
A meta-analysis completed by Li and colleagues
analyzed data from nine studies involving 417
participants on the use of metformin dosed at
0.5–3 g/day for NAFLD.4 The primary outcome
was histological response to therapy, including
steatosis, inflammation, hepatocellular ballooning, and fibrosis. No significant difference was
seen in any of the variables between metformin
and diet and exercise alone; this was also true for
a subgroup analysis of patients with diabetes versus those without. A limitation of this meta-analysis is that only five of the nine studies could be
assessed for the primary outcome due to provision of insufficient data in the individual studies.
A study completed by Nair and colleagues
included patients with NAFLD who took metformin (20 mg/kg/day in three divided doses) for
48 weeks and compared pre- and post-treatment
liver biopsies.8 Ten of 15 patients completed both
biopsies; of these only three saw a reduction in
steatosis at the study’s conclusion.
journals.sagepub.com/home/tae
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Although the data on improvements in histologic
outcomes with metformin in NAFLD have been
poor, improvements in metabolic markers have
been seen in two meta-analyses and several
smaller studies (Table 1). An important benefit of
metformin therapy is its contribution to weight
loss, possibly through its impact on insulin sensitivity and the gastrointestinal adverse effects associated with its use.9 Improvements in body mass
index (BMI) from baseline were seen in the metaanalysis by Li and colleagues with a weight loss of
–0.82 kg/m2 (p < 0.04).4 Significant improvements in the homeostatic model assessment for
insulin resistance (HOMA-IR) scores were seen
in the meta-analysis by Li and colleagues (p =
0.04)4 and Mazza and colleagues (p = 0.003)9,
indicating improvements in insulin sensitivity. A
study completed by Loomba and colleagues
found that patients with a lower baseline BMI
responded more significantly to metformin therapy than those with a baseline BMI of at least 40
in terms of weight loss, reductions in HOMA-IR,
and histological improvements.5 The authors
concluded that there is a positive correlation
between weight loss and improvements in hepatocellular injury and inflammation. Mild to moderate increases in alanine aminotransferase (ALT)
is the most common laboratory finding in
NAFLD, and improvements in ALT and aspartate aminotransferase (AST) have been seen with
metformin treatment in almost all patients in the
reviewed studies.4,8–10 These decreases do tend to
be more significant after the first three months of
treatment, at which time AST/ALT levels generally plateau.8
Another contributing factor to obesity and
NAFLD is leptin, a hormone produced by adipose tissue to indicate fullness during mealtime as
well as to regulate the collection of lipids to the
adipose sites.3 Patients with obesity can experience leptin resistance, and high serum levels of
leptin were seen in patients with NAFLD.3,11
Increases in leptin can impact proinflammatory
responses and fibrogenesis as well as modify the
effects of insulin on hepatic fat metabolism and
increase insulin resistance.3,11 A small study (n =
34) looked at the effects of metformin in patients
with NAFLD in regards to decreases in serum
leptin in comparison to a lifestyle modification
intervention.11 Leptin was significantly reduced
in both groups from baseline to month 6 (p =
0.039 in the lifestyle group and p = 0.047 in the
metformin group), but there was no difference
between the groups. Leptin levels were reduced
journals.sagepub.com/home/tae

in correlation with amount of weight loss in both
groups, further emphasizing the importance of a
focus on weight management in patients with
NAFLD.
Thiazolidinediones
It could be hypothesized that thiazolidinediones
(TZDs) are well suited for use in the treatment of
NASH due to their powerful insulin-sensitizing
properties. TZDs bind to peroxisome proliferator-activated receptor γ receptors and improve
insulin sensitivity in the liver, skeletal muscle, and
adipose tissue.12,13 In addition, they increase
plasma adiponectin levels14 and decrease proinflammatory cytokines,15 all of which are primary
processes involved in NASH. Several studies
examined the use of rosiglitazone and pioglitazone in patients with impaired glucose tolerance
or T2DM and biopsy proven NASH (Table 2).
Efficacy. Two trials16,17 examined rosiglitazone
use in patients with biopsy-confirmed NASH. In
one trial,16 rosiglitazone was studied in an openlabel design in 30 subjects, half of those with
either T2DM or impaired glucose tolerance, to
determine if rosiglitazone would improve insulin
sensitivity, improve hepatic steatosis, and reduce
serum liver aminotransferases. At the end of 48
weeks, serum levels of ALT and AST decreased
significantly from baseline. Significant improvements in histologic markers, specifically steatosis
(p = 0.004) and ballooning (p = 0.003), were
observed. While significant changes in the characteristic and pattern of fibrosis were seen, no significant difference in the global fibrosis score was
observed (p = 0.583). Importantly, approximately
half of the participants were nonresponders. For
those who did respond to rosiglitazone, transaminases returned to baseline values 6 months after
stopping treatment. The second study, a randomized controlled trial completed by Ratziu and colleagues, compared rosiglitazone with placebo in
63 subjects, 20 with T2DM.17 At the end of 12
months, significantly more patients in the rosiglitazone group achieved over 30% reduction in steatosis (47% versus 16%, p = 0.014) and
normalized serum ALT levels (38% versus 7%, p
= 0.005) compared with placebo. Additional clinical improvements in HOMA-IR, fasting insulin
level, and adiponectin level were noted. Similar to
the first trial, there were no significant improvements seen in fibrosis, and 50% of subjects were
nonresponders. Nonresponders had higher
γ-glutamyltransferase levels, higher instances of
17
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Table 1. Efficacy and safety trials of metformin for NAFLD in patients with T2DM.
Study and
trial
design

Treatment

Comparator

Number of
Participants

Duration
(months
unless
otherwise
stated)

ALT
mean
change
from
baseline

AST
mean
change
from
baseline

Imaging or
histologic
changes

Other significant
measurements

Li et al.4
Metaanalysis

MET

Diet/diet +
exercise/
various PBO

417
(68 with DM
or IGT)

6 or 12

–8.12 U/
liter, p =
0.03

–4.52 U/
liter, p =
0.04

No changes
seen in
steatosis,
inflammation,
ballooning, or
fibrosis

HOMA-IR
changes were
statistically
significant in
patients with
NAFLD but not
NASH

Loomba
et al.5

MET 2000
mg/day

26
(15 with DM)

48 weeks

↓ 7 U/
liter

↓ 4 U/
liter

Presence of
NASH
Pre: 26/26
Post: 18/26
NASH activity
index
Pre: 8.2 (1.5)
Post: 5.9 (2.2)
(p < 0.001)

Average weight ∆
–6 kg (range +1.3
to −18.9 kg)
Strong positive
correlation
between weight
loss and changes
in serum
aminotransferase
levels; higher
baseline BMI
↓response
HOMA-IR ∆ –3.4
(p < 0.04)

Nair et al.8
Open label

MET 20
mg/kg/day
(max 2 g)

15
(1 with DM)

1 year

↑ 6 IU/
liter

↓ 6 IU/
liter

20% of patients
showed
improvement
in degree of
steatosis at 1
year

BMI ∆ –1.7% (p <
0.05)
HOMA-IR ∆ –0.09
(p < 0.05)

Haukeland
et al.10
RCT

MET 2500
mg/day

PBO

48
(12 with DM)

6

MET: 22
U/liter,
p = 0.025
PBO: 15
U/liter,
p = 0.025

MET: 8 U/
liter,
p = 0.036
PBO: no
change

Treatment was
associated
with a slight
reduction of
liver steatosis
in both groups
Age, baseline
HOMA-IR, ∆ in
body weight:
independently
associated with
change in liver
steatosis

MET caused
weight loss (–4.3
± 4.3 kg) (p ⩽
0.001)
MET group had
a significant
change in leptin
levels (p ⩽ 0.001)
MET significantly
lowered LDL
levels, mean ∆
–27 mg/dl (p <
0.001); no change
in PBO group

Nar and
Gedik11

MET 1700
mg/day
plus
diet and
exercise

Diet and
exercise

34
(all with DM)

6

MET: 16
U/liter,
p = 0.015
Lifestyle:
7 U/liter,
p = 0.047

No
change
(either
group)

Liver
echogenicity
decreased
significantly in
both groups

MET group
decreased LDL ∆
–23 (p = 0.002)
MET group
increased HDL ∆
+4 (p = 0.035)

ALT, alanine aminotransferase; AST, aspartate aminotransferase, BMI, body mass index; DM, diabetes mellitus; HDL, high-density lipoprotein;
HOMA-IR, homeostatic model assessment insulin resistance; LDL, low-density lipoprotein; MET, metformin; NAFLD, nonalcoholic fatty liver
disease; NASH, nonalcoholic steatohepatits; PBO, placebo; RCT, randomized controlled trial.
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Treatment

ROS 4 mg twice
daily

ROS 4 mg/day
titrated to 8
mg/day after 1
month

ROS 4 mg twice
daily

Study and trial
design

NeuschwanderTetri et al.16
Open label

Ratziu et al.17
RCT

journals.sagepub.com/home/tae

Torres et al.18
Randomized open
label

ROS 4 mg plus
MET 500 mg
twice daily
ROS 4 mg twice
daily plus LOS 50
mg/day

PBO

None

Comparator

108
(18 with DM)

63
(20 with DM)

30
(8 with diabetes,
7 with IGT)

Number of
participants

12

ROS –44%
ROS + MET
–47%
ROS + LOS
–52%
p < 0.001
overall

ROS: ALT
normalized in 12
subjects (38%)
PBO: ALT
normalized in 2
subjects (7%)
p = 0.005

–54%, p < 0.001

12

12

ALT mean
change from
baseline

Duration
(months
unless
otherwise
stated)

ROS –32%
ROS + MET
–38%
ROS + LOS
–36%
p < 0.001
overall

–43.3%, p =
0.003

AST mean
change from
baseline

Table 2. Efficacy and safety trials of thiazolidinediones for NAFLD in patients with T2DM.

–62.5%, p <
0.001

γ-GT mean
change from
baseline

Steatosis improved
ROS 27%
ROS + MET 30%
ROS + LOS 26%
p < 0.001 overall
Hepatocellular inflammation
ROS 36%
ROS + MET 25%
ROS + LOS 21%
p < 0.001 overall
Fibrosis improved
ROS 50%
ROS + MET 50%
ROS + LOS 21%
p < 0.001 overall

>30% improvement in
steatosis
ROS 47%
PBO 16%
p = 0.014
Ballooning
NS
Fibrosis
ROS NS
PBO NS
Inflammation
ROS NS
PBO NS

Steatosis
14 improved, p = 0.004
1 worsened
Ballooning
11 improved, p = 0.003
Fibrosis
8 improved, p = 0.583
3 worsened

Imaging or histologic
changes

(Continued)

Participants with diabetes had
significant improvements in NAS
compared with those without
diabetes, p = 0.046
Mostly due to steatosis, p = 0.006
Overall, no added benefit was seen
above ROS alone compared with
combination groups with respect to:
Steatosis, p = 0.905
Hepatocellular inflammation, p =
0.46
Fibrosis, p = 0.302
NAS, p = 0.671
Resolution of NASH (% of
participants)
ROS 46%
ROS + MET 36%
ROS + LOS 29%

Mean Δ body weight kg (SD)
ROS: +1.5 (5.2)
PBO: –1.0 (3.5)
p = 0.03
Mean Δ HOMA-IR
ROS –1.4
PBO 0.61
p < 0.001
Mean Δ fasting insulin level (µUI/ml)
ROS –4.8 (9.2)
PBO 2.1 (14.8)
p < 0.002
Mean Δ adiponectin level (µg/mL)
ROS 1.91 (1.39)
PBO 0.94 (0.23)
p = 0.04

Mean Δ BMI
6.5% (range –5% to 18%), p < 0.001
Mean Δ HOMA-IR
–3.5, p < 0.001

Other significant measurements

EP Mills, K Trotta et al.
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Treatment

MET 1700 mg/
day

PIO 45 mg/day
+ hypocaloric
diet

PIO 45 mg/
day plus
hypocaloric
diet

Study and trial
design

Omer et al.19
Open label,
randomized

Gastaldelli et al.20
RCT

Belfort et al.21
RCT

Table 2. (Continued)

Placebo plus
hypocaloric diet

PBO +
hypocaloric diet

ROS 4 mg/day
and MET 1700
mg/day + ROS 4
mg/day

Comparator

48; 10 healthy
controls

6

6

PIO –58%
PBO –34%
p < 0.001

MET –26%, NS
ROS –56%, p <
0.0001
MET+ROS
–31%, p = 0.017
p values pre–
post in-group
comparison

12

64
(all with DM or
IGT)

47 with IGT or
DM; 20 healthy
controls

ALT mean
change from
baseline

Duration
(months
unless
otherwise
stated)

Number of
participants

PIO –40%
PBO –21%
p = 0.04

Steatosis improved
PIO 65%
PBO 38%
p = 0.003
Ballooning improved
PIO 54%
PBO 24%
p = 0.02
Fibrosis improved
PIO 46%
PBO 33%
p = 0.08

Mean Δ body fat % (body weight)
PIO 1.5% (+2.5±0.5 kg)
PBO –4% (–3.2 ± 0.5 kg)
p = 0.005
Mean Δ fasting plasma insulin
PIO –34%
PBO no change
p ⩽ 0.001
Mean Δ FFA levels
PIO –17%
PBO no change
p = 0.044

Improvements in FFA metabolism
PIO versus PBO 20% difference,
p = 0.01
Adipo-IR decreased by ~47% in PIO
group compared with baseline
p = 0.03
Strong correlations were found in
improvement in Adipo-IR and the
following for the PIO group only:
Steatosis decreased ~50% (r =
0.29, p = 0.049)

Mean Δ BMI:
MET –3.2, p = 0.002
ROS –0.3, NS
MET+ROS –1.3, p = 0.006
Mean Δ fasting plasma insulin
MET –23%, NS
ROS –33%, p = 0.005
MET+ROS –33%, p ⩽ 0.005
Mean Δ HOMA-IR
MET –18%, NS
ROS –38%, p = 0.003
MET+ROS –28%, NS
Only 35/64 subjects had
follow-up biopsies
NAFLD score improvement
(n)
MET (10): +0.7, p = 0.726
ROS (13): –2.6, p = 0.012
MET+ROS(12): –3.9, p =
0.026

MET –49%,
NS
ROS +30%,
NS
MET+ROS
–56%, p =
0.008

MET –28%, NS
ROS –25%, p =
0.005
MET+ROS
–30%, p = 0.01

Necroinflammation improved
PIO 44%
PBO 12%
p ⩽ 0.001

Other significant measurements

Imaging or histologic
changes

γ-GT mean
change from
baseline

AST mean
change from
baseline

Therapeutic Advances in Endocrinology and Metabolism 9(1)
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Resolution of NASH
PIO 51%
PBO 19%
treatment difference of 32
percentage points (CI 13–51); p <
0.001
Mean Δ fibrosis score
PIO –0.5
PBO 0
Treatment difference −0.5 (CI −0.9
to 0); p = 0.039
NAS improved by ⩾ 2 points
PIO 58%
PBO 17%
treatment difference of
41 percentage points (CI
23–59); p < 0.001
36
(18 blinded
18 open
label)
101
(all with DM or
IGT)
PBO +
hypocaloric diet
PIO 45 mg/day
+ hypocaloric
diet
Cusi et al.22
RCT

journals.sagepub.com/home/tae

ALT, alanine aminotransferase; AST, aspartate aminotransferase, BMI, body mass index; CI, confidence interval; DM, diabetes mellitus; FFA, free fatty acid; γ-GT, γ glutamyl transferase;
HOMA-IR, homeostatic model assessment insulin resistance; IGT, impaired glucose tolerance; LOS, losartan; MET, metformin; NAS, NAFLD Activity Score; NASH, nonalcoholic
steatohepatits; NS, not significant; PBO, placebo; PIO, pioglitazone; RCT, randomized controlled trial; ROS, rosiglitazone; SD, standard deviation; IGT impaired glucose tolerance.

Other significant measurements
Comparator
Treatment
Study and trial
design

Table 2. (Continued)

Number of
participants

Duration
(months
unless
otherwise
stated)

ALT mean
change from
baseline

AST mean
change from
baseline

γ-GT mean
change from
baseline

Imaging or histologic
changes
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diabetes, lower adiponectin levels, and lower
amounts of steatosis. Four months after treatment, serum transaminases returned to baseline
levels.
Combination treatments with rosiglitazone and
metformin have been investigated. Torres and
colleagues compared rosiglitazone with metformin or with the combinations rosiglitazone
plus metformin or rosiglitazone plus losartan and
reported significant within-group improvements
in steatosis, necroinflammation, ballooning and
fibrosis (p < 0.001 for all); there was no significant between-group difference suggesting no
benefit to adding metformin or losartan to rosiglitazone in NASH treatment.18
When data from subjects with diabetes were analyzed separately, NAFLD Activity Score (NAS)
significantly improved in patients with diabetes
compared with those without, mostly due to
improvement in steatosis (p = 0.006). Omer and
colleagues compared metformin with rosiglitazone or the combination of rosiglitazone plus
metformin for the treatment of NASH in 64 subjects with T2DM or impaired glucose tolerance.19
Significant within-group differences were
observed for reductions in serum ALT and AST
levels and NAS scores for the rosiglitazone and
rosiglitazone plus metformin groups but not for
the metformin group. HOMA-IR reduced significantly in the rosiglitazone group (p < 0.05) only.
No significant change in fibrosis was noted in any
treatment group.
In a randomized placebo-controlled trial by
Gastaldelli and colleagues, histologic and metabolic effects of pioglitazone were compared with
placebo for the treatment of NASH in patients
with T2DM or impaired glucose tolerance.20
Patients in both groups maintained a calorierestricted diet by reducing their intake by 500
kcal/day. Changes in glucose and lipid metabolism, as well as adipose tissue insulin resistance
(Adipo-IR) were reported. At baseline, in comparison to a control group without NASH,
patients with NASH were found to have significantly lower plasma adiponectin levels, two to
three times the concentration of plasma insulin
levels, and significantly higher plasma FFA concentrations. These metabolic differences are
indicative of systemic and adipose tissue insulin
resistance and were found to be true for obese as
well as lean subjects with NASH. At the end of six
months, pioglitazone significantly reduced FFA
21
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concentrations and reduced Adipo-IR by around
47% (p = 0.03). According to Belfort and colleagues, pioglitazone, compared with placebo,
significantly reduced serum transaminases,
decreased fasting plasma insulin, and decreased
FFA levels.21 Additionally, pioglitazone treatment resulted in significantly greater improvements in steatosis (65% versus 38%, p = 0.003),
ballooning (54% versus 24%, p = 0.02), and combined mean necroinflammation score (44% versus
12%, p = 0.001) over placebo. Consistent with
other trials assessing TZDs, there was no significant difference in reduction of fibrosis for pioglitazone over placebo (46% versus 33%, p = 0.08).
A recently published trial by Cusi and colleagues
describes the results from a three-year study of
efficacy and safety of pioglitazone in participants
with prediabetes or T2DM and biopsy-proven
NASH.22 After the initial 18 months, more
patients randomized to pioglitazone achieved the
primary endpoint of at least two points’ improvement in the NAS than placebo (58% versus 17%,
p < 0.00). In addition, pioglitazone was more
effective than placebo at NASH resolution (51%
versus 19%, p < 0.001) and mean change in fibrosis scores (–0.5 versus 0, p = 0.039). Despite this,
progression of any fibrosis continued in both
groups but was significantly lower in the pioglitazone group compared with placebo (12% versus
28%, p = 0.039). Histologic and metabolic
improvements were maintained for the entire
study period of three years.
Safety. While it has been observed that long-term
treatment with a TZD is necessary to sustain clinical improvements, concern exists over the safety
of prolonged use. No serious adverse events
reported were related to TZD treatment.16–22 In
the three-year study, no osteoporosis, osteoporotic bone fractures, or bladder cancer was
detected.22 The most notable adverse events
reported were reduction in hemoglobin, median
decrease 0.7 g/dl (0.1–3.1 g/dl),16 lower limb
edema,17,21,22 and weight gain (1.5–6.4 kg).16,17,21
Glucagon-like peptide-1 receptor agonists
Agents in the glucagon-like peptide-1 receptor agonist (GLP-1 RA) class improve glycemic control in
individuals with T2DM through multiple mechanisms, including glucose-dependent insulin secretion, decreased glucagon secretion, slowed gastric
emptying, and enhanced satiety.23 Historically,
GLP-1 receptors have been identified in the
22

pancreas, kidney, lung, gastric mucosa, heart,
hypothalamus,24 and most recently in the liver.25 In
murine models, GLP-1 RAs were shown to improve
transaminase levels, reduce oxidative stress, and
reduce hepatic steatosis, making them viable
options for the treatment of NASH (Table 3).26–28
Efficacy. Two trials assessed the metabolic and
hepatic effects of exenatide immediate release.
Fan and colleagues compared exenatide with
metformin in participants with T2DM and
NAFLD.27 At baseline, 52% of participants had
abnormal liver function, with 46 participants having an ALT over 2.5 times the upper limit of normal (ULN). The second study, conducted by
Shao and colleagues, compared exenatide plus
insulin glargine U-100 with intensive insulin
treatment with insulin glargine U-100 plus insulin aspart.28 Included patients had hepatic injury
biomarkers between 2.5 and 5 times the ULN;
‘normal’ for each was defined as ALT or AST up
to 40 U/liter and γ glutamyl transferase (γ-GT) up
to 50 U/liter. Exenatide was initiated at 5 μg twice
daily for the first 4 weeks to minimize gastrointestinal effects and titrated to 10 μg twice daily for
the remaining 8 weeks in both studies.
All arms of both studies showed improvement in
hepatic markers. Fan and colleagues found exenatide to be superior to metformin in improving
ALT, AST, and γ-GT.27 Additionally, C-reactive
protein (CRP) was significantly decreased and
adiponectin was significantly increased in the
exenatide arm, suggesting improved oxidative
stress. Mean reductions in body weight and BMI
were statistically significant for the exenatide
group compared with the metformin group.
Lastly, both exenatide and metformin improved
insulin resistance similarly, measured by
HOMA-IR. In the study by Shao and colleagues
comparing exenatide plus glargine with glargine
plus aspart, body weight and waist circumference
were significantly decreased in the exenatide arm,
but increased in the intensive insulin arm.28 The
post-treatment mean for ALT, AST, and γ-GT
levels was statistically lower in the exenatide arm
compared with the insulin only arm. Exenatide in
combination with glargine was also superior to
insulin alone in the reversal rate of fatty liver disease, which was 93.3% and 66.7% (p < 0.01),
respectively.
The efficacy of liraglutide in patients with T2DM
and NASH was assessed in two separate trials by
the same primary investigator. In the first published
journals.sagepub.com/home/tae
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PBO
GLI 4 mg/day

PBO

MET 500 mg
twice daily,
adjusted up
to 2 g/day

iGLAR daily
(+) iASP
three times
daily

LIR 0.6, 1.2,
and 1.8 mg

LIR 1.8 mg

EXE 5 μg
twice daily
for 30 days,
increased to
10 μg twice
daily

iGLAR daily
(+) EXE 5 μg
twice daily
for 30 days,
increased to
10 μg twice
daily

Armstrong
et al.
(LEAD)25

Armstrong
et al.
(LEAN)26

Fan et al.27

Shao
et al.28

60
(all with DM)

117
(all with DM)

45
(17 with DM)

149
(all with DM)

Number of
participants

12 weeks

12 weeks

48 weeks

26 weeks

Duration

EXE: 42.51
(13.12); INS
only: 67.37
(15.78); p <
0.001

EXE: 27.32
(15.96);
MET: 12.85
(11.38); p =
0.002

LIR: 26.6
(34.4); PBO:
10.2 (35.8);
p = 0.16

ALT mean
change from
baseline
(SD)

EXE: 32.28
(8.71); INS
only: 42.90
(10.0); p <
0.001

EXE: 7.89
(7.87); MET:
5.11 (6.98);
p = 0.048

LIR: 15.8
(21.8); PBO:
8.6 (28.3);
p = 0.29

AST mean
change
from
baseline
(SD)

EXE: 34.37
(10.05); INS
only: 43.36
(3.60); p <
0.001

EXE: 26.48
(17.34);
MET: 10.26
(14.11); p =
0.000

LIR: 33.7
(42.5); PBP:
7.2 (28.3);
p = 0.01

γ-GT mean
change
from
baseline
(SD)

Reversal rate
of fatty liver
(regression from
greater to lower
degree of fatty
liver): EXE, 93.3%;
INS only, 66.7%;
p < 0.01

LSAR
improvement with
LIR versus PBO:
mean difference
+0.10 (95% CI
–0.01 to 0.20;
p = 0.07)

Imaging or
histologic
changes

Mean Δ BMI (SD):

Mean Δ CRP (SD): EXE,
0.89 (0.59); MET, 0.61
(0.54); p = 0.018
Mean Δ adiponectin
(SD): EXE, 1.86 (2.22);
MET, 0.76 (1.3); p =
0.001
Mean Δ BMI (SD): EXE,
1.31 (0.98); MET, 0.69
(0.94); p = 0.000
Mean Δ HOMA-IR (SD):
EXE, 0.57 (0.36); MET
0.56 (0.49); p = 0.367

Mean Δ BMI (SD): LIR,
1.8 (1.67); PBO, 0.3 (1.7);
p = 0.005
Mean Δ HOMA-IR (SD):
LIR, 1.8 (3.7); PBO, 0.70
(9.49); p = 0.23

Other significant
measurements

ALT, alanine aminotransferase; AST, aspartate aminotransferase, BMI, body mass index; CI, confidence interval; CRP, C-reactive protein; EXE, exenatide; INS, insulin; iASP, insulin
aspart; iGLAR, insulin glargine; γ-GT, γ glutamyl transferase; GLI, glimepiride; HOMA-IR, homeostatic model assessment insulin resistance; LEAN, liraglutide efficacy and action in
NASH; LIR, liraglutide; LSAR, liver-to-spleen attenuation ratio; MET, metformin; NS, not significant; PBO, placebo; SD, standard deviation; DM diabetes mellitus.

Comparator

Treatment

Study

Table 3. Efficacy and safety trials of glucagon-like peptide 1 receptor agonists for NAFLD in patients with T2DM.
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study, the investigators performed a meta-analysis
of the LEAD (liraglutide efficacy and action in diabetes) program.25 For the purposes of this article,
only the LEAD-2 substudy is reviewed as it is the
only trial with confirmed presence of fatty liver disease. In the LEAD-2 substudy, hepatic steatosis
was measured by computer tomography (CT)
imaging at randomization and conclusion of the
study and confirmed in 64.4% of individuals at
baseline. A liver-to-spleen attenuation ratio (LSAR)
of less than 1.0 defined hepatic steatosis and an
improvement in steatosis was an increase in the
LSAR. Participants were given metformin in combination with liraglutide 0.6, 1.2, or 1.8 mg/day or
active placebo (glimepiride 4 mg/day or placebo). A
dose-dependent increase in LSAR was seen with
liraglutide 1.8 mg, but it was nonsignificant. No
significant differences in LSAR were seen between
the lower doses of liraglutide and placebo.
The second study on liraglutide by Armstrong
and colleagues, the LEAN (liraglutide efficacy
and action in NASH) study, is a more robust
assessment of liraglutide in participants with
biopsy-confirmed NASH.26 The study enrolled
52 participants, but only nine participants (35%)
in the liraglutide arm and eight participants (31%)
in the placebo arm had a diagnosis of T2DM.
Liraglutide was titrated over 14 days to 1.8 mg
per day and participants were allowed to remain
on previous treatment with metformin, sulfonylurea, or a combination. Three participants (38%)
with T2DM in the treatment group achieved the
primary outcome of resolution of NASH with no
worsening of fibrosis whereas none of the participants with T2DM in the placebo arm were able
to achieve this outcome. Progression of fibrosis
was observed in two participants (9%) in the liraglutide group and eight participants (36%) in the
placebo group. Compared with placebo, the relative risk for participants with T2DM taking liraglutide achieving resolution of NASH without
worsening fibrosis was 4.7 [95% confidence interval (CI) 0.3–75.0; p = 0.20]. Participants in the
liraglutide arm did have statistically significant
decreases in body weight, BMI, and γ-GT levels.
Interestingly, this study included participants
with stage 3 fibrosis and cirrhosis; study investigators observed that participants with more
advanced disease had positive treatment effects
from liraglutide, but not as pronounced as participants with mild to moderate disease.
Safety. Despite the slow titration of exenatide over
4 weeks, gastrointestinal side effects were listed in
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both exenatide trials as the predominant side
effect in the treatment arm, but did not contribute
to study withdrawl.27,28 Adverse events were similar between liraglutide and placebo in the LEAN
study, with the exception of gastrointestinal disorders, which were more common in the liraglutidetreated arm.27 The information provided on safety
from the LEAD-2 substudy is underwhelming
and not delineated between the main LEAD program analysis and LEAD-2 substudy; available
safety data indicate that gastrointestinal side
effects and hepatobiliary serious adverse events
were comparable for liraglutide 1.2, liraglutide
1.8, and placebo for participants with normal and
abnormal ALT levels at baseline.25
Antihyperlipidemics
In addition to the benefits HMG-CoA (3-hydroxy3-methyl-glutaryl-coenzyme A) reductase inhibitors (statins) have on lipids, they improve insulin
sensitivity, decrease production of advanced glycation endproducts (AGEs), and display antiinflammatory effects, all of which may be helpful
in treating the steatosis and inflammation associated with NASH.29,30 Several studies evaluate the
use of lipid medications as treatment options for
NASH, including atorvastatin, simvastatin, rosuvastatin, pitavastatin, ezetimibe/simvastatin combination, and ursodeoxycholic acid (UDCA), a
bile acid used to reduce cholesterol absorption
(Table 4).30
Efficacy. In 2003, Kiyici and colleagues completed
a prospective study comparing UDCA with atorvastatin in the treatment of NASH.30 In a small
study of 44 patients, both groups saw significant
lowering in ALT and γ glutamyl transferase
(GGT), an enzyme used as a diagnostic marker
for liver disease (p < 0.02). The atorvastatin group
at baseline had higher cholesterol levels; after the
study period, a decrease in serum cholesterol was
seen in the atorvastatin group as well as a statistically significant normalization of transaminases
post treatment (p = 0.021). Imaging studies found
that liver densities did increase in the atorvastatin
group. There was no change in BMI, serum glucose, or triglyceride levels in either group.
The PITCH study, a 2012 prospective randomized open-label trial by Han and colleagues
compared pitavastatin (2–4 mg per day) with
atorvastatin (10–20 mg/day).31 Over 12 weeks,
the 135 study participants showed a statistically
significant lowering (p < 0.05) in serum GGT
journals.sagepub.com/home/tae
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ATO 10 mg

UDCA 13–15 mg/
kg/day in
normolipidemic
patients

PIT 2–4 mg/day

ATO 10 mg/day

SIM 20 mg/day

SIM 40 mg/day

Kimura
et al.29

Kiyici
et al.30

Han
et al.31

Hyogo
et al.32

Abel
et al.33

Nelson
et al.34

PBO

EZE/SIM 10/10
mg/day

ATO 10–20 mg/
day

ATO 10
mg/day in
hyperlipidemic
patients

Comparator

16
(7 with DM)

45
(all with DM)

31
(22 with IGT or
DM)

189
(53 with DM)

44
(10 with DM)

43
(31 with IGT or
DM)

Number of
participants

12

6

24

12 weeks

6

12

Duration
(months)

SIM, NS
PBO, NS
SIM versus PBO, NS

SIM: –37 7 U/liter,
p < 0.0001
EZE/SIM: –31 U/
liter, p < 0.0001
SIM versus EZE/SIM,
p < 0.0112

–53.5 U/liter,
p < 0.001

PIT: –5 U/liter,
p = 0.047
ATO, NS

UDCA: –19 U/liter;
p = 0.002
ATO: –37 U/liter;
p = 0.0001
UDCA versus ATO:
NS

–33.5 U/liter; p <
0.001

ALT mean change
from baseline

SIM, NS
PBO, NS
SIM versus PBO,
NS

SIM: –35.6 U/
liter, p < 0.0001
EZE/SIM: –27.1
U/liter, p <
0.0001
SIM versus EZE/
SIM, p < 0.0001

–25.3 U/liter, p <
0.001

PIT, NS
ATO, NS

UDCA: NS
ATO: –13 U/liter;
p = 0.004
UDCA versus
ATO: p = 0.033

–15.8 U/liter; p <
0.001

AST mean
change from
baseline

NR

NR

–36 U/liter, p <
0.001

PIT: –10.9 U/liter,
p = 0.034
ATO: –11.1 U/
liter, p = 0.040

UDCA: –15.6 U/
liter (p = 0.016)
ATO: –27 U/liter
(p = 0.014)
UDCA versus
ATO: NS

–25.3 U/liter; p <
0.001

γ-GT mean
change from
baseline

Δ hepatic steatosis,
necroinflammatory
activity, fibrosis stage:
NS in either group or
between groups

Steatosis grade and NAS:
improved, p < 0.001
Fibrosis: worsened in 4
patients

Δ TC, LDL, TG: NS in either
group or between groups

Δ TC, HDL, TG: NS in either
group or between groups
Δ LDL: SIM versus EZE/SIM,
p = 0.0063
Δ CK U/L: NS in either group

Transaminases normalized in
74.2% of patients
Δ BMI, FBG, HbA1c, NS
Δ HS CRP: decrease, p < 0.05
Δ HOMA-IR, NS

Equal reduction in LDL, p <
0.0001
Increase in ALT: 17 patients; 2
severe (>3 × ULN)

BMI, serum glucose and TG
level changes: NS for both
groups

UDCA: NS
ATO: significant increase
in liver density (improved
steatosis); p = 0.0001
UDCA versus ATO: NS
change in steatosis
Hepatic steatosis
improvement:
PIT, p = 0.008
ATO, NS

Δ BMI, FBG: unchanged
Fibrosis stage
Improved: 9%
Unchanged: 59%
Worsened: 32%

Other significant
measurements

Liver density increased;
p < 0.001
Necroinflammatory
grade improved; p < 0.05
NAS
Improved: 68%
Unchanged: 27%
Worsened: 5%

Imaging or histologic
changes

ALT, alanine aminotransferase; AST, aspartate aminotransferase; ATO, atorvastatin; BMI, body mass index; CK, creatine kinase; CRP, C-reactive protein; DM, diabetes mellitus; EZE/
SIM, ezetimibe/simvastatin; FBG, fasting blood glucose; γ-GT, γ glutamyl transferase; HbA1c, glycosylated hemoglobin; HDL, high-density lipoprotein; HOMA-IR, homeostatic model
assessment insulin resistance; HS CRP, high-sensitivity C-reactive protein; IGT, impaired glucose tolerance; LDL, low-density lipoprotein; NAS, NAFLD Activity Score; NR, not reported;
NS, not significant; PBO, placebo; PIT, pitavastatin; TG, triglyceride; UDCA, ursodeoxycholic acid; ULN, upper limit of normal; SIM simvastatin TC total cholesterol.

Treatment

Study

Table 4. Efficacy and safety trials of HMG CoA reductase inhibitors for NAFLD in patients with T2DM.
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concentrations and LDL cholesterol (p < 0.0001)
from baseline in both treatment groups. Only the
pitavastatin group had significantly reduced ALT,
which was the primary endpoint. Tomography
revealed that both groups reduced hepatic steatosis severity in patients with overt fatty liver before
randomization.
Two additional studies investigated the use of
atorvastatin 10 mg per day in combination with
standard weight loss counselling.29,32 A controlled
trial by Hyogo and colleagues followed patients
over 24 months, twice the length of patients followed in the open-label trial by Kimura and colleagues. Hyogo and colleagues found a mean
change in both ALT and AST from baseline
whereas Kimura also found a change in γ-GTP.
No changes in BMI or serum glucose were found
in either study; however, Hyogo and colleagues
also evaluated for changes in adiponectin, tumor
necrosis factor α, leptin, and long chain fatty
acids. Overall, no statistically significant changes
were found in these values. Both studies showed
improvement in NAFLD score and liver steatosis
grade. Kimura and colleagues additionally
reviewed the effects of atorvastatin on AGEs, as
they are commonly increased in patients with
NASH. Atorvastatin was found to decrease AGEs
significantly.29,32
A randomized, double-blind, placebo-controlled
trial by Nelson and colleagues investigated the
use of simvastatin 40 mg versus placebo in the
treatment of NASH.34 Over 12 months, 16
patients were not found to have a statistically significant improvement in ALT or AST from baseline, hepatic steatosis, necroinflammatory activity,
or fibrosis stage for either the treatment or placebo group. An additional retrospective trial by
Abel and colleagues compared simvastatin 20 mg
with ezetimibe/simvastatin 10 mg/10 mg over six
months.33 Both groups resulted in a statistically
significant change in ALT and AST from baseline
(p < 0.0001 for all groups), and simvastatin monotherapy decreased both ALT and AST significantly more than combination therapy (p <
0.0112 and p < 0.0001, respectively). Overall,
there was no difference between the two groups in
regards to cholesterol decrease, triglyceride
reduction, and HDL elevation.
Safety. Adverse effects of statin therapies used in
the aforementioned trials ranged from elevations
in ALT to a progression of fibrosis. Of the atorvastatin studies, there was no report of an elevation
26

in transaminases.29,30,32 However, the PITCH
study reported an elevation in ALT in both the
pitavastatin and atorvastatin treatment groups,
with one study participant from each treatment
group being excluded from analysis as a result of
severely elevated ALT.31 Progression in fibrosis
staging was found in atorvastatin treatment
groups in two of the studies that utilized atorvastatin.29,32 The studies involving simvastatin did
not reveal any adverse effects of the therapy.33,34
Discussion
Based on the reviewed studies, metformin, TZDs,
GLP-1 RAs, and statins all appear to be safe
options for the treatment of NAFLD/NASH in
patients with concomitant T2DM, but efficacy
data surrounding each vary. Metformin shows little positive impact on histological markers associated with NAFLD. The benefit from metformin
treatment can be attributed to improvement in
weight and metabolic profile. Data from reviewed
studies on metformin reiterated that weight management in patients with NAFLD has the most
benefit on steatosis.7
The mechanism of TZDs to improve insulin
sensitivity in the liver, muscle, and adipose tissue has shown effectiveness in reversing NASH
in up to half of treated patients, but may need to
be continued indefinitely to avoid return to baseline.16,17 TZDs provide significant histologic and
metabolic improvements overall, but did not
provide significant differences in fibrosis compared with placebo. While it is not fully understood why some patients do not respond to TZD
treatment, one trial found a higher rate of nonresponders in those with T2DM.17 Conversely,
another trial reported NAS scores significantly
improved in those with diabetes versus those
without.18
Improvements in liver disease in patients on
GLP-1 RAs were detected through reduced
hepatic enzymes and liver histology via biopsy or
imaging in patients with NAFLD and T2DM.
These improvements may be attributed to the
beneficial effects GLP-1 RAs have on liver
inflammation, insulin resistance, and body
weight. Based on the available data, GLP-1 treatment appears to be of benefit in individuals with
mild to moderate NAFLD and T2DM, and may
offer some advantages in advanced disease (e.g.
cirrhosis), albeit a lessened effect for a very costly
medication.
journals.sagepub.com/home/tae
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Atorvastatin is the most commonly studied statin
in the treatment of NAFLD/NASH. Overall,
atorvastatin appears to be moderately beneficial
in decreasing transaminases, the severity of
hepatic steatosis, and the NAS score. One study
also noted the importance of reducing AGEs and
the ability of atorvastatin to decrease those levels
in patients with dyslipidemia. However, the overall ability of AGEs to be utilized as an indicative
biomarker for NASH warrants further investigation.29 Certain trials included patients only with
dyslipidemia; therefore, the role of statins in the
treatment of NASH in patients with normal lipids
needs to be further investigated.30
Along with diet, exercise, and glycemic control,
the discussed medications may be a viable option
for the treatment of NAFLD. In addition to their
insulin-sensitizing benefits, they may improve the
prognosis of NAFLD in patients with T2DM by
decreasing the risk of serious consequences, such
as cardiovascular disease and hepatocellular carcinoma.35 Conflicting trial results, small cohorts,
and short study durations emphasize the need for
continued studies on the most viable and efficacious pharmacologic treatment options for
patients with NAFLD and T2DM.
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